dc.creator | Salvador-Martín, Sara | es |
dc.creator | Kaczmarczyk, Bartosz | es |
dc.creator | Álvarez, Rebeca | es |
dc.creator | Navas-López, Víctor Manuel | es |
dc.creator | Gallego-Fernández, Carmen | es |
dc.creator | Moreno-Álvarez, Ana | es |
dc.creator | Merino Bohórquez, Vicente | es |
dc.creator | López-Fernández, Luís A. | |
dc.date.accessioned | 2021-02-10T10:38:09Z | |
dc.date.available | 2021-02-10T10:38:09Z | |
dc.date.issued | 2021-01-08 | |
dc.identifier.citation | Salvador-Martín, S., Kaczmarczyk, B., Álvarez, R., Navas-López, V.M., Gallego-Fernández, C., Moreno-Álvarez, A.,...,Merino-Bohórquez, V. (2021). Whole transcription profile of responders to anti-tnf drugs in pediatric inflammatory bowel disease. Pharmaceutics, 13 (1), 1-17. | |
dc.identifier.issn | 1999-4923 | es |
dc.identifier.uri | https://hdl.handle.net/11441/104820 | |
dc.description.abstract | Background: Up to 30% of patients with pediatric inflammatory bowel disease (IBD) do not respond to anti-Tumor Necrosis Factor (anti-TNF) therapy. The aim of this study was to identify pharmacogenomic markers that predict early response to anti-TNF drugs in pediatric patients with IBD. Methods: An observational, longitudinal, prospective cohort study was conducted. The study population comprised 38 patients with IBD aged < 18 years who started treatment with infliximab or adalimumab (29 responders and nine non-responders). Whole gene expression profiles from total RNA isolated from whole blood samples of six responders and six non-responders taken before administration of the biologic and after two weeks of therapy were analyzed using next-generation RNA sequencing. The expression of six selected genes was measured for purposes of validation in all of the 38 patients recruited using qPCR. Results: Genes were differentially expressed in non-responders and responders (32 before initiation of treatment and 44 after two weeks, Log2FC (Fold change) >0.6 or <−0.6 and p value < 0.05). After validation, FCGR1A, FCGR1B, and GBP1 were overexpressed in non-responders two weeks after initiation of anti-TNF treatment (Log2FC 1.05, 1.21, and 1.08, respectively, p value < 0.05). Conclusion: Expression of the FCGR1A, FCGR1B, and GBP1 genes is a pharmacogenomic biomarker of early response to anti-TNF agents in pediatric IBD | es |
dc.description.sponsorship | Instituto de Salud Carlos III número de becas PI16 / 00559 y PI19 / 00792 | es |
dc.description.sponsorship | Consejería de Educación y Deporte de la Comunidad de Madrid PEJ16 / MED / AI-1260 | es |
dc.description.sponsorship | Instituto de Investigaciones Sanitarias Gregorio Marañón PRE2018-2 | es |
dc.description.sponsorship | Fondos Europeos de Desarrollo Regional (FEDER) del Comisión Europea | es |
dc.format | application/pdf | es |
dc.format.extent | 17 | es |
dc.language.iso | eng | es |
dc.publisher | MDPI | es |
dc.relation.ispartof | Pharmaceutics, 13 (1), 1-17. | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Biomarker | es |
dc.subject | Gene expression | es |
dc.subject | Infliximab | es |
dc.subject | Adalimumab | es |
dc.subject | Ulcerative colitis | es |
dc.subject | Crohn disease | es |
dc.subject | Inflammatory bowel disease | es |
dc.title | Whole transcription profile of responders to anti-tnf drugs in pediatric inflammatory bowel disease | es |
dc.type | info:eu-repo/semantics/article | es |
dcterms.identifier | https://ror.org/03yxnpp24 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Farmacología, Pediatría y Radiología | es |
dc.relation.projectID | PI16 / 00559 y PI19 / 00792 | es |
dc.relation.projectID | PEJ16 / MED / AI-1260 | es |
dc.relation.projectID | PRE2018-2 | es |
dc.relation.publisherversion | https://doi.org/10.3390/pharmaceutics13010077 | es |
dc.identifier.doi | 10.3390/pharmaceutics13010077 | es |
dc.journaltitle | Pharmaceutics | es |
dc.publication.volumen | 13 | es |
dc.publication.issue | 1 | es |
dc.publication.initialPage | 1 | es |
dc.publication.endPage | 17 | es |